Veracity Capital LLC Lowers Stake in Amgen Inc. (NASDAQ:AMGN)

Veracity Capital LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 952 shares of the medical research company’s stock after selling 46 shares during the period. Veracity Capital LLC’s holdings in Amgen were worth $307,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of AMGN. Security Financial Services INC. raised its position in Amgen by 5.1% during the first quarter. Security Financial Services INC. now owns 968 shares of the medical research company’s stock worth $275,000 after acquiring an additional 47 shares during the period. Northwest Investment Counselors LLC lifted its position in shares of Amgen by 7.5% in the first quarter. Northwest Investment Counselors LLC now owns 3,603 shares of the medical research company’s stock valued at $1,024,000 after acquiring an additional 250 shares in the last quarter. CHICAGO TRUST Co NA boosted its stake in shares of Amgen by 6.4% in the first quarter. CHICAGO TRUST Co NA now owns 8,487 shares of the medical research company’s stock worth $2,413,000 after acquiring an additional 513 shares during the last quarter. AdvisorNet Financial Inc increased its position in shares of Amgen by 5.7% during the first quarter. AdvisorNet Financial Inc now owns 2,206 shares of the medical research company’s stock worth $627,000 after purchasing an additional 119 shares in the last quarter. Finally, Peak Financial Advisors LLC acquired a new position in Amgen in the 1st quarter valued at $2,827,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on AMGN shares. Sanford C. Bernstein assumed coverage on shares of Amgen in a research note on Thursday. They set an “outperform” rating and a $380.00 target price on the stock. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. TD Cowen raised their target price on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $329.48.

Amgen Trading Up 0.1 %

AMGN opened at $321.66 on Friday. Amgen Inc. has a 52 week low of $249.70 and a 52 week high of $346.85. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The business has a fifty day simple moving average of $326.07 and a 200-day simple moving average of $312.15. The firm has a market cap of $172.55 billion, a P/E ratio of 45.95, a P/E/G ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the business earned $5.00 earnings per share. On average, equities analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.80%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s payout ratio is currently 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.